NexImmune (NEXI) Competitors $0.0002 0.00 (0.00%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NEXI vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. NexImmune vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity NexImmune (NASDAQ:NEXI) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Do institutionals and insiders have more ownership in NEXI or ATNFW? 9.9% of NexImmune shares are held by institutional investors. 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer NEXI or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than NexImmune. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for NexImmune. 180 Life Sciences' average media sentiment score of 1.88 beat NexImmune's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment NexImmune Neutral 180 Life Sciences Very Positive Is NEXI or ATNFW more profitable? 180 Life Sciences' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets NexImmuneN/A -534.32% -213.72% 180 Life Sciences N/A N/A N/A Which has preferable earnings and valuation, NEXI or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNexImmuneN/AN/A-$32.34M-$18.540.00180 Life SciencesN/AN/AN/AN/AN/A Summary180 Life Sciences beats NexImmune on 4 of the 6 factors compared between the two stocks. Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$848.51M$5.78B$9.79BDividend YieldN/A4.84%3.95%4.02%P/E Ratio0.001.1331.2726.59Price / SalesN/A26.55435.63155.76Price / CashN/A19.5637.7359.36Price / Book0.006.7310.966.68Net Income-$32.34M-$4.20M$3.27B$265.59M7 Day PerformanceN/A16.11%1.44%0.62%1 Month PerformanceN/A17.10%6.24%2.61%1 Year PerformanceN/A34.92%55.09%22.34% NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/A$0.00flatN/A-100.0%$0.00N/A0.006ATNFW180 Life SciencesN/A$0.22+10.1%N/A+2,713.9%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.24-40.2%N/AN/A$0.00$110.87K0.0040Gap UpALVOWAlvotechN/A$1.16-0.7%N/A-55.5%$0.00$560.10M0.004ACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+6.5%N/A+139.5%$0.00N/A0.0015BFRIWBiofronteraN/A$0.14+42.6%N/AN/A$0.00$39.19M0.0070Gap DownBTMDWbioteN/A$0.01-10.6%N/A-95.8%$0.00$199.07M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.02+8.9%N/A-94.3%$0.00N/A0.008Gap UpCELUWCelularityN/A$0.05+6.2%N/A+201.5%$0.00$54.22M0.00220Positive NewsGap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Alvotech Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Celularity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEXI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access